Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating the safety and disease activity of combining Telisotuzumab Adizutecan with Osimertinib as first-line treatment for adults …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Snippet

Sponsor: AbbVie | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING